UNSPSC 51385003: Zomepirac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 822G987U9J, chemically known as 5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrole-2-acetic acid but generally known as zomepirac, which bears US NIH Compound Identifier 5733. European Medicines Agency schedules Zomepirac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00185MIG.

UNSPSC 51385003 Zomepirac is a Commodity code intended for pharmaceutical procurement, though recent state and local solicitation activity under this code shows a mismatch with its nominal scope. The single recent opportunity posted under this code — Seminole County, Florida's IFB 60459723LAS — actually solicits naloxone and drug deactivation systems for community health support, not zomepirac (an NSAID analgesic). This mismatch suggests either a coding error in the source data or inconsistent application of the taxonomy by the issuing body. State and local procurement offices use the commodity code to classify pharmaceutical purchases; when properly applied, the code would capture individual drug products and related medical supplies procured by county health departments, school districts, municipalities, and other public bodies for emergency response, treatment programs, and public health initiatives.

Seminole County, Florida represents the sole recent activity visible under this code. The county posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023 (a date that appears inconsistent with the posting date and may reflect a source error). The procurement calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. The contract term is two years with an optional one-year renewal, and bidders must meet standard compliance requirements including drug-free workplace certification, E-Verify confirmation, and specified insurance coverages. The procurement does not designate explicit set-asides or disadvantaged-enterprise preferences. Beyond this single opportunity, the source does not support characterization of geographic spread, issuing-body concentration, or activity patterns under the code.